Biologics, Wound Care, Infection Prevention
Israeli PolyPid Ready for Clinical Trials of Anti-Infective Surgical Products
PolyPid expects to use a $22 million cash infusion to get its surgical drug reservoir lead candidate into Phase III testing, while completing a trial for its doxycycline-loaded synthetic bone substitute. The latter, for BonyPid-1000, is expected to be sufficient...